Market research
CNTB Connect Biopharma Holdings Ltd
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 128M
- P/E ratio
- Not available
- Analyst target
- 7.25
- Dividend yield
- Not available
- Beta
- -0.18
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- KYG235491019
- Market cap
- 128M
- P/E ratio
- Not available
- Analyst target
- 7.25
- Dividend yield
- Not available
- Beta
- -0.18
About
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the CNTB discussion.
No comments yet
Start a focused discussion about CNTB.